Market

The pharmacist stood at the centre of the three-day event that witnessed scientific symposia, poster presentations, a job fair and…

Vision 2025 report unveiled

Seminar addresses challenges faced by manufacturers in their endeavour to reach global markets

India is in a position to elevate Neglected Tropical Diseases (NTDs) and build awareness on how their control and elimination will…

$250 million to be payable upon satisfaction of certain regulatory conditions

Partners with BioAsia as principal country partner

Financial figures for the acquisition were undisclosed

Is indicated for the treatment of schizophrenia, and for the treatment of acute manic episodes associated with bipolar disorder

Expects to generate a cumulative revenue of $20 million within five years of the launch

Otsuka’s phase III clinical trials for delamanid are now underway